Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT03278665 |
| Title | 4SC-202 in Combination With Pembrolizumab in Patients Primary Refractory/Non-responding to Prior Anti-PD-1 Therapy (SENSITIZE) |
| Acronym | SENSITIZE |
| Recruitment | Completed |
| Gender | both |
| Phase | Phase Ib/II |
| Variant Requirements | No |
| Sponsors | 4SC AG |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | ITA | DEU |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| Universitätsklinikum Essen | Essen | Germany | Details | |||
| Medizinische Hochschule Hannover | Hannover | Germany | Details | |||
| Universitätsklinikum Heidelberg | Heidelberg | Germany | Details | |||
| Klinikum der Universität München | München | Germany | Details | |||
| Universitätsklinikum Tübingen | Tübingen | Germany | Details | |||
| Universitätsklinikum Würzburg | Würzburg | Germany | Details | |||
| Istituto Nazionale Tumori Fondazione "G. Pascale" | Napoli | Italy | Details |